Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Up 2.2% – Here’s What Happened

Posted by Geri Gentry on Jul 31st, 2026

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Free Report)’s stock price traded up 2.2% on Thursday . The company traded as high as $1.42 and last traded at $1.42. 109,808 shares were traded during mid-day trading, an increase of 20% from the average daily volume of 91,223 shares. The stock had previously closed at $1.39.

Wall Street Analysts Forecast Growth

ACXP has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen upgraded shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $31.00.

Read Our Latest Analysis on Acurx Pharmaceuticals

Acurx Pharmaceuticals Trading Up 2.2%

The firm has a market capitalization of $6.11 million, a P/E ratio of -0.35 and a beta of -2.05. The business has a 50 day moving average of $1.61 and a 200-day moving average of $2.29.

Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.03). On average, analysts anticipate that Acurx Pharmaceuticals, Inc. will post -1.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ACXP. Armistice Capital LLC acquired a new stake in Acurx Pharmaceuticals in the 2nd quarter valued at approximately $551,000. Millennium Management LLC acquired a new position in Acurx Pharmaceuticals during the 4th quarter worth approximately $103,000. Geode Capital Management LLC acquired a new position in Acurx Pharmaceuticals during the 4th quarter worth approximately $31,000. Finally, Jane Street Group LLC bought a new position in shares of Acurx Pharmaceuticals during the 4th quarter worth approximately $27,000. 11.53% of the stock is owned by institutional investors and hedge funds.

About Acurx Pharmaceuticals

(Get Free Report)

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).